Mariner’s Lucid Diagnostics LUCD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$46.2K Buy
43,146
+21,993
+104% +$23.7K ﹤0.01% 3419
2026
Q1
$24.3K Buy
21,153
+7,293
+53% +$9.28K ﹤0.01% 3482
2025
Q4
$15.1K Buy
+13,860
New +$15.5K ﹤0.01% 3501
2025
Q2
Sell
-10,163
Closed -$15.1K 3602
2025
Q1
$15.1K Buy
+10,163
New +$12.2K ﹤0.01% 3395

Other funds holding LUCD

Mariner's LUCD Position: Q2 2026 in Review

Mariner increased its Lucid Diagnostics (LUCD) stake by 104% in Q2 2026, buying an estimated $23.7K and bringing the position to 43,146 shares worth $46.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3419.

Mariner first reported a position in LUCD in Q1 2025 and has held it in 4 quarters since. 116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Mariner held 43,146 shares of Lucid Diagnostics worth $46.2K as of Q2 2026.
  • Mariner bought 21,993 Lucid Diagnostics shares in Q2 2026, an estimated $23.7K.
  • Lucid Diagnostics made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3419 holding.
  • Mariner first reported a position in Lucid Diagnostics in Q1 2025 and has held it in 4 quarters since.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.